Pfizer and Merck today announced that the two parties since January 1, 2016 Pfizer formal joint promotion targeting cancer drugs Sai Rui ® (g azole erlotinib) in Chinese market. This is an important strategic move in August 2015, Pfizer and Merck, a global strategic alliance official visit in China after. This will combine Pfizer and Merck Medical Resources, innovative experiences and professional team in China, so that more Chinese ALK-positive non-small cell lung cancer (NSCLC) patients benefit, and continue to promote the development of China in the field of cancer therapy immunity.
"Sai Rui ® joint promotion is a global alliance with Merck, Pfizer landing in China," the head of one of the joint promotion - president of Pfizer tumor Greater single country Ang said, "the significance of this cooperation is to He began to focus on the resources and strengths of both companies to maximize the benefit of Chinese cancer patients in China to promote the field of oncology and immunology latest targeted therapy oncology drugs faster, better and more widely available so that patients have access to timely, accurate diagnosis and treatment. of this strategic cooperation, the joint promotion is just the beginning, we believe that in the future, except for lung cancer drugs, there will be more and tumor-related products in the Chinese market, so that more Chinese Cancer patients benefit. "
没有评论:
发表评论